DEM Biopharma, Inc. Alternatives & Competitors

12 companies similar to DEM Biopharma, Inc. — Novel Target for Solid Tumors

Exelixis

Exelixis works on discovering, developing, and commercializing therapies for the treatment...

1566 IPO $340.26M

Alameda, United States

Biotechnology

Pentixapharm AG

improves the life of patients with malignant diseases through targeted molecular diagnosti...

37 Series A $15.00M

Wurzburg, Germany

Biotechnology Health Care +2

Myricx Bio

Developing a new class of ADCs based on NMT inhibition to treat cancer

36 Undisclosed $1.59B

London, United Kingdom

Biotechnology Health and Wellness +1

NiKang Therapeutics Inc.

37 Series C $260.00M

Wilmington, United States

Biotechnology Health Care

Track all DEM Biopharma, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

RayzeBio

Targeted innovative radiopharmaceuticals for cancer

258 Acquired $4.78B

San Diego, United States

Biotechnology Health Care +2

ONCOCROSS Co., Ltd.

AI, drug discovery development, biotechnology, indication expansion, rare disease, intract...

18 Corporate Round $18.00B

Seoul, Korea South

Biotechnology Pharmaceutical

Indi Molecular

Indi Molecular is an emerging life sciences company developing synthetic molecules with an...

2 Series A $11.50M

Culver City, United State...

Biotechnology Health Care

Prelude Therapeutics

Precision Oncology, Redefined.

126 Post Ipo Equity $147.00M

Wilmington, United States

Biopharma Biotechnology +2

AUROBAC THERAPEUTICS

Tackling bacterial infections, antimicrobial resistance, and their consequences in acute c...

31 Seed

Lyon, France

Biopharma Health Care +2

Celyad Oncology

19 Post Ipo Equity $135.80M

Belgium

Biotechnology Health and Wellness +1

Light Chain Bioscience | Novimmune SA

Light Chain Bioscience – A brand of Novimmune SA

76 Series C

Plan-les-ouates, Switzerl...

Biotechnology Pharmaceutical

Arcellx

Arcellx is a clinical-stage biotechnology company based in Redwood City, California

224 Acquired $8.43B

Redwood City, United Stat...

Biopharma Biotechnology +3

About DEM Biopharma, Inc.

Novel Target for Solid Tumors

Services

Research and Development, Poster Presentation, Therapeutics Innovation

Target Customers

Healthcare Professionals, Oncologists, Medical Researchers, Hospitals, Pharmaceutical Companies

Taxonomy

Cancer Therapeutics, Immuno-Oncology, Antibody-Drug Conjugate, Solid Tumors, Extracellular Protein Targeting, Gastrointestinal Malignancies, Innate Immune System Checkpoints, Biopharmaceuticals, Oncology Innovation, Novel Cancer Targets, ADC Development

Business Model

B2B

Revenue Model

Licensing, Product Sales, Performance Based

Frequently Asked Questions

Top alternatives to DEM Biopharma, Inc. include Exelixis, Pentixapharm AG, Myricx Bio, NiKang Therapeutics Inc., RayzeBio. These companies serve similar markets and are frequently compared.

Bounce Watch tracks 12 companies similar to DEM Biopharma, Inc. based on industry overlap, target customers, and business model.

Novel Target for Solid Tumors

Don't just read about them. Follow them.

BounceWatch watches DEM Biopharma, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

DEM Biopharma, Inc. Profile Exelixis Alternatives Pentixapharm AG Alternatives Myricx Bio Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at DEM Biopharma, Inc. on 18 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.